144 related articles for article (PubMed ID: 38102639)
1. Evaluating the cost-effectiveness of [
Tew M; Douglas AP; Szer J; Bajel A; Harrison SJ; Tio SY; Worth LJ; Hicks RJ; Ritchie D; Slavin MA; Thursky KA; Dalziel K
Cancer Imaging; 2023 Dec; 23(1):119. PubMed ID: 38102639
[TBL] [Abstract][Full Text] [Related]
2. [
Douglas A; Thursky K; Spelman T; Szer J; Bajel A; Harrison S; Tio SY; Bupha-Intr O; Tew M; Worth L; Teh B; Chee L; Ng A; Carney D; Khot A; Haeusler G; Yong M; Trubiano J; Chen S; Hicks R; Ritchie D; Slavin M
Lancet Haematol; 2022 Aug; 9(8):e573-e584. PubMed ID: 35777413
[TBL] [Abstract][Full Text] [Related]
3. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
[TBL] [Abstract][Full Text] [Related]
4. FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial.
de Koster EJ; Vriens D; van Aken MO; Dijkhorst-Oei LT; Oyen WJG; Peeters RP; Schepers A; de Geus-Oei LF; van den Hout WB;
Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3452-3469. PubMed ID: 35435497
[TBL] [Abstract][Full Text] [Related]
5. Comparison of CT, MRI, and F-18 FDG PET/CT for initial N-staging of oral squamous cell carcinoma: a cost-effectiveness analysis.
Burian E; Palla B; Callahan N; Pyka T; Wolff C; von Schacky CE; Schmid A; Froelich MF; Rübenthaler J; Makowski MR; Gassert FG
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3870-3877. PubMed ID: 35606526
[TBL] [Abstract][Full Text] [Related]
6. The clinical utility of fluorodeoxyglucose-positron emission tomography for investigation of fever in immunocompromised children.
Wang SS; Mechinaud F; Thursky K; Cain T; Lau E; Haeusler GM
J Paediatr Child Health; 2018 May; 54(5):487-492. PubMed ID: 29235187
[TBL] [Abstract][Full Text] [Related]
7. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems.
Robin P; Kumar S; Salaun PY; Le Roux PY; Couturaud F; Planquette B; Merah A; Roy PM; Thavorn K; Le Gal G
Thromb Res; 2018 Nov; 171():97-102. PubMed ID: 30268859
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the use of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the workup of Staphylococcus aureus bacteraemia: a cost-utility analysis.
Ong SWX; Zhabokritsky A; Daneman N; Tong SYC; Wijeysundera HC
Clin Microbiol Infect; 2023 Nov; 29(11):1417-1423. PubMed ID: 37353076
[TBL] [Abstract][Full Text] [Related]
9.
Gassert FG; Rübenthaler J; Cyran CC; Rink JS; Schwarze V; Luitjens J; Gassert FT; Makowski MR; Schoenberg SO; Mayerhoefer ME; Tamandl D; Froelich MF
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3268-3276. PubMed ID: 33686457
[TBL] [Abstract][Full Text] [Related]
10. An economic evaluation of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence.
Auguste P; Barton P; Hyde C; Roberts TE
Health Technol Assess; 2011 Apr; 15(18):iii-iv, 1-54. PubMed ID: 21524363
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of routine (18)F-FDG PET/CT in high-risk patients with gram-positive bacteremia.
Vos FJ; Bleeker-Rovers CP; Kullberg BJ; Adang EM; Oyen WJ
J Nucl Med; 2011 Nov; 52(11):1673-8. PubMed ID: 21984799
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules.
Gould MK; Sanders GD; Barnett PG; Rydzak CE; Maclean CC; McClellan MB; Owens DK
Ann Intern Med; 2003 May; 138(9):724-35. PubMed ID: 12729427
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective probabilities and economic modelling.
Meads C; Auguste P; Davenport C; Małysiak S; Sundar S; Kowalska M; Zapalska A; Guest P; Thangaratinam S; Martin-Hirsch P; Borowiack E; Barton P; Roberts T; Khan K
Health Technol Assess; 2013 Mar; 17(12):1-323. PubMed ID: 23537558
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of 18F-FDG PET/CT in detecting suspected recurrence or metastasis in well-differentiated thyroid carcinoma patients with negative diagnostic total body scan in Thailand: a decision analysis.
Khiewvan B; Nopmaneejumruslers C; Pusuwan P; Tuchinda P; Tojinda N; Ubolnuch K
J Med Assoc Thai; 2013 Oct; 96(10):1350-64. PubMed ID: 24350419
[TBL] [Abstract][Full Text] [Related]
15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
16. Added value of positron emission tomography imaging in the surgical treatment of colorectal liver metastases.
Wiering B; Adang EM; van der Sijp JR; Roumen RM; de Jong KP; Comans EF; Pruim J; Dekker HM; Ruers TJ; Krabbe PF; Oyen WJ
Nucl Med Commun; 2010 Nov; 31(11):938-44. PubMed ID: 20856152
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission.
Huntington SF; Svoboda J; Doshi JA
J Clin Oncol; 2015 May; 33(13):1467-74. PubMed ID: 25823735
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of 18F-FDG PET/CT, MRI and CE-CT in selection of colorectal liver metastases eligible for ablation - A cost-effectiveness analysis.
Schnitzer ML; Buchner J; Biechele G; Grawe F; Ingenerf M; von Münchhausen N; Kaiser CG; Kunz WG; Froelich MF; Schmid-Tannwald C; Rübenthaler J
Eur J Radiol; 2023 Jun; 163():110803. PubMed ID: 37004464
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach.
Vriens D; Adang EM; Netea-Maier RT; Smit JW; de Wilt JH; Oyen WJ; de Geus-Oei LF
J Clin Endocrinol Metab; 2014 Sep; 99(9):3263-74. PubMed ID: 24873995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]